SEARCH:   Advanced

Blood, 1 January 2009, Vol. 113, No. 1, pp. 154-164. Prepublished online as a Blood First Edition Paper on October 7, 2008; DOI 10.1182/blood-2007-10-119438. This Article Full Text Full Text (PDF) Supplemental Table and Figures All Versions of this Article: blood-2007-10-119438v1 113/1/154    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kornblau, S. M. Articles by Mills, G. B. Search for Related Content PubMed PubMed Citation Articles by Kornblau, S. M. Articles by Mills, G. B. Related Collections Myeloid Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  MYELOID NEOPLASIA Functional proteomic profiling of AML predicts response and survival Steven M. Kornblau1,*, Raoul Tibes2,*, Yi Hua Qiu1, Wenjing Chen1, Hagop M. Kantarjian3, Michael Andreeff1, Kevin R. Coombes4, and Gordon B. Mills5 1 Departments of Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston; 2 Translational Genomics Research Institute, Phoenix/Scottsdale, AZ; and 3 Departments of Leukemia, 4 Bioinformatics and Computational Biology, and 5 Systems Biology, University of Texas M. D. Anderson Cancer Center, Houston Because protein function regulates the phenotypic characteristics of cancer, a functional proteomic classification system could provide important information for pathogenesis and prognosis. With the goal of ultimately developing a proteomic-based classification of acute myeloid leukemia (AML), we assayed leukemia-enriched cells from 256 newly diagnosed AML patients, for 51 total and phosphoproteins from apoptosis, cell-cycle, and signal-transduction pathways, using reverse-phase protein arrays. Expression in matched blood and marrow samples were similar for 44 proteins; another 7 had small fold changes (8%-55%), suggesting that functional proteomics of leukemia-enriched cells in the marrow and periphery are similar. Protein expression patterns were independent of clinical characteristics. However, 24 proteins were significantly different between French-American-British subtypes, defining distinct signatures for each. Expression signatures for AML with cytogenetic abnormalities involving –5 or –7 were similar suggesting mechanistic commonalities. Distinct expression patterns for FMS-like tyrosine kinase 3–internal tandem duplication were also identified. Principal component analysis defined 7 protein signature groups, with prognostic information distinct from cytogenetics that correlated with remission attainment, relapse, and overall survival. In conclusion, protein expression profiling patterns in AML correlate with known morphologic features, cytogenetics, and outcome. Confirmation in independent studies may also provide pathophysiologic insights facilitating triage of patients to emerging targeted therapies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. S. Neeley, S. M. Kornblau, K. R. Coombes, and K. A. Baggerly Variable slope normalization of reverse phase protein arrays Bioinformatics, June 1, 2009; 25(11): 1384 - 1389. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020